Atorvastatin (Lipitor)

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Also Known As:

Networked: 4942 relevant articles (697 outcomes, 1664 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cannon, Christopher P: 46 articles (01/2018 - 04/2002)
2.	Ballantyne, Christie M: 36 articles (08/2017 - 01/2003)
3.	Athyros, Vasilios G: 35 articles (07/2021 - 01/2002)
4.	Kastelein, John J P: 35 articles (01/2019 - 12/2002)
5.	Waters, David D: 33 articles (01/2019 - 09/2002)
6.	Mikhailidis, Dimitri P: 33 articles (01/2014 - 01/2002)
7.	Olsson, Anders G: 28 articles (01/2017 - 01/2001)
8.	Nicholls, Stephen J: 26 articles (01/2022 - 11/2005)
9.	Braunwald, Eugene: 25 articles (07/2019 - 04/2002)
10.	Nissen, Steven E: 24 articles (01/2019 - 03/2004)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 01/01/2020 - "20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk." 08/01/2004 - "Our data demonstrate that atorvastatin induces a significant improvement of diabetic dyslipidemia and a significant increase of LPL activity. " 10/01/2021 - "Atorvastatin is effective in the treatment of dyslipidemias. " 11/01/2015 - "Low-dose atorvastatin was effective for treatment of dyslipidemia in RA patients but had no apparent effect on RA disease activity." 01/01/2015 - "Atorvastatin (ATV) is widely used for the treatment of dyslipidemias. "
2.	Hypercholesterolemia 06/01/1997 - "Atorvastatin is highly effective and well tolerated in patients with primary hypercholesterolemia with no increased risk of adverse events." 11/01/2020 - "Currently, the child is on Atorvastatin, a RAS inhibitor, already available in the market for the treatment of hypercholesterolemia and has shown considerable improvement in global behaviour and cognitive development. " 01/01/2020 - "Biodegradable polymeric microneedles containing atorvastatin calcium were developed in order to improve the percutaneous absorption of the drug, useful for the treatment of hypercholesterolemia. " 06/01/2009 - "A multicenter study was conducted to assess the efficacy of a generic form of Atorvastatin (Ranbaxy's Storvas) in the treatment of Primary Hypercholesterolemia. " 01/01/2006 - "We concluded that atorvastatin not only improved hypercholesterolemia, but also reduced CRP even in Japanese diabetic patients. "
3.	Hyperlipidemias (Hyperlipidemia) 01/01/2007 - "Moreover atorvastatin improved although not completely normalized parameters of postprandial lipemia: significant lowering of baseline (-17%), 3 (-19%) and 6 hour (-14%) post load TG levels was noted. " 02/01/2015 - "Acupuncture combined with administration of Lipitor is effective in improving primary hyperlipidemia in patients, which is superior to administration of simple Lipitor." 10/01/2002 - "Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? " 07/01/2002 - "In conclusion, low-dose atorvastatin appears to be safe, well tolerated, and effective in the treatment of post-transplant hyperlipidemia. " 12/01/2003 - "The use of atorvastatin in NASH patients with hyperlipidemia was found to be both effective and safe. "
4.	Inflammation (Inflammations) 12/24/2013 - "After 12 weeks, there was a significant reduction in periodontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (ΔTBR 80 mg vs. 10 mg group: mean -0.43 [95% CI: -0.83 to -0.02], p = 0.04). " 01/01/2009 - "This study suggests that atorvastatin is effective in reducing inflammation, biochemical hyperandrogenemia, and metabolic parameters in patients with PCOS after a 12-wk period." 02/01/2008 - "Firstly, our results showed that ASA and atorvastatin combined treatment was effective in reducing inflammatory status in HD patients independently of body composition: at the end of the study only 7.49% of the patients exhibited PINI>1. Further studies will be necessary to understand the causes of inflammation in non-responder patients." 01/01/2012 - "Atorvastatin treatment may be effective in slowing the decline of beta cell function in a patient subgroup defined by above median levels of CRP and other inflammation associated immune mediators. " 11/01/2008 - "In conclusion, pre-operative atorvastatin treatment in patients undergoing elective CABG decreased inflammation parameters and could be effective in preventing SIRS."
5.	Type 2 Diabetes Mellitus (MODY) 12/01/2005 - "The recently published Collaborative Atorvastatin Diabetes Study (CARDS), a placebo-controlled trial conducted solely in patients with type 2 diabetes, terminated 2 years earlier than its anticipated length owing to the significant reduction in number of CV events observed in patients randomized to receive low-dose atorvastatin versus placebo. " 02/01/2002 - "In conclusion, treatment with atorvastatin in type 2 diabetes led to a significant improvement in endothelium-dependent vasodilation, which might be partly related to its anti-inflammatory effect." 04/01/2013 - "We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). " 01/01/2005 - "Atorvastatin treatment was associated with an improvement in the stiffness of leg arteries in type 2 diabetes mellitus. " 01/01/2021 - "We used data from the 4D study, enrolling 1255 haemodialysis patients with type 2 diabetes mellitus, randomised to atorvastatin or placebo and followed for a composite cardiovascular endpoint. "

Related Drugs and Biologics

1.	Lipids
2.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
3.	Simvastatin (Zocor)
4.	Rosuvastatin Calcium (Crestor)
5.	oxidized low density lipoprotein
6.	Cholesterol
7.	LDL Cholesterol
8.	Pravastatin (Pravachol)
9.	Ezetimibe (Zetia)
10.	C-Reactive Protein

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Percutaneous Coronary Intervention
4.	Transplantation
5.	Renal Dialysis (Hemodialysis)